Ariad (ARIA) Receives Approval of Iclusig (Ponatinib) in Israel

Shares of Ariad Pharmaceuticals Inc. (ARIA) are up 3.62% to $8.88 in pre-market trading Tuesday following an announcement from the Israeli Ministry of Health granting the company and Medison Pharma regulatory approval for Iclusig (ponatinib) in Israel. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of […] View the full post at: Ariad (ARIA) Receives Approval of Iclusig (Ponatinib) in Israel No related posts.